Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Press Releases

Press Releases

Year

June 2, 2023

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

May 8, 2023

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

May 2, 2023

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

March 27, 2023

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

March 6, 2023

Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa

February 23, 2023

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

February 9, 2023

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

January 6, 2023

Aclaris Therapeutics Provides 2023 Outlook

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2023 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.